A Phase 1 interventional study of Myrin© 2 (Rifampicin + Isoniazid) and Rimactane® (Rifampicin) in Tuberculosis, sponsored by Pfizer. Completed at 1 site in Philippines. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-07-30.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing rifampin in Tuberculosis — 6 open to participants now, 7 under way, 3 of them phase 3. Rifampin · Tuberculosis.
Among the 34 studies testing rifampin in Tuberculosis, this one is the 26th largest by enrollment, is one of 3 that started in 2011, is one of 10 in phase 1, and was the 11th registered.
1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.
Browse Tuberculosis studies →6 of the 34 studies testing rifampin in Tuberculosis are open now, in 12 countries. Recruiting first, the newest first:
University College, London · Sites in Pakistan, South Africa, Zimbabwe
Ages 16+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in Brazil, India, Kenya and 9 more countries
Ages 15+
Michael Hoelscher · Sites in Gabon, Malawi, Mozambique and 3 more countries
Ages 18–65
University of Wisconsin, Madison · Sites in Peru
Ages 3 mo–9 yrs
Miguel Santín
Ages 18–85
By country, each count listing its studies:
Rifampin: first FDA approval 1971 (RIFADIN). What it is approved for, and how studies give it, is on its page →
Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 150 across 820 interventional studies indexed under Tuberculosis.
Median enrollment 129 across the 34 interventional studies. Of the 22 that completed or were terminated, 7 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 34 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 4 studies filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing rifampin in Tuberculosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05807399Michael HoelscherPanACEA - STEP2C -01 | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies testing rifampin in Tuberculosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is done to demonstrate bioequivalence of rifampicin component in Myrin© 2 Fixed-Dose Combination Tablet (each contains 75 mg isoniazid and 150 mg rifampicin, Pfizer Inc) with equivalent dose of the reference Rimactane® capsule (each contains 300 mg rifampicin, Novartis Sandoz) in healthy Filipino male subjects. This study also aims to determine the safety and tolerability of Myrin© 2 tablets and Rimactane® capsules in these subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Test
Drug: Myrin© 2 (Rifampicin + Isoniazid)
Reference
Drug: Rimactane® (Rifampicin)
Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
Also known as: Myrin© 2 (Pfizer Inc.)
One (1) capsule of Rifampicin 300 mg
Also known as: Rimactane® (Novartis Sandoz)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t])
AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hours (hrs) post-dose
Maximum Observed Plasma Concentration (Cmax)
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])
AUC (0-∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose
Plasma Decay Half-life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose
Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)
AUC%extrapolated is the extrapolated area under the plasma concentration time profile following the last measured concentration. It is calculated as (AUC \[0-∞\] minus AUC\[0-10\])\*100/ AUC (0-∞), where AUC (0-∞) = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUC(0-10) = area under the plasma concentration time-curve from zero (pre-dose) to the last quantifiable concentration.
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose
Number of Participants With Abnormal Safety Laboratory Test Values
Participants were evaluated for following safety laboratory tests: Hematology, chemistry, urinalysis.
Time frame: Screening and Follow-up (1 week post-baseline)
Clinically Significant Change From Baseline Supine Blood Pressure (BP)
Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.
Time frame: Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)
Clinically Significant Change From Baseline Pulse Rate
Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.
Time frame: Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)
Clinically Significant Change From Baseline Oral Temperature
Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.
Time frame: Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)
Clinically Significant Change From Baseline Respiratory Rate
Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.
Time frame: Baseline (Day 0), Day 1 (Hour 10), and follow-up (1 week post-baseline)
Number of Participants With Adverse Events (AEs)
Any untoward medical occurrence in a participant who received study treatment was considered an AE without regard to possibility of causal relationship.
Time frame: Baseline (Day 0), Day 1 and Follow-up (1 week post-baseline)
| Milestone | Myrin 2 First, Then Rimactane | Rimactane First, Then Myrin 2 |
|---|---|---|
| Started | 10 | 11 |
| Completed | 10 | 10 |
| Not completed | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Milestone | Myrin 2 First, Then Rimactane | Rimactane First, Then Myrin 2 |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
| Milestone | Myrin 2 First, Then Rimactane | Rimactane First, Then Myrin 2 |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)
| microgram*hour/milliliter (mcg*h/mL) | Myrin 2 | Rimactane |
|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t]) | 38.59 ± 24.99 | 38.81 ± 21.95 |
| mcg/mL | Myrin 2 | Rimactane |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 7.89 ± 24.89 | 8.02 ± 22.35 |
| hrs | Myrin 2 | Rimactane |
|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 2.0 (1.0 to 3.0) | 1.0 (1.0 to 3.0) |
AUC (0-∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
| mcg*hr/mL | Myrin 2 | Rimactane |
|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞]) | 47.72 ± 30.54 | 47.15 ± 25.32 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hrs | Myrin 2 | Rimactane |
|---|---|---|
| Plasma Decay Half-life (t1/2) | 4.0750 ± 1.0777 | 3.8635 ± 0.8347 |
AUC%extrapolated is the extrapolated area under the plasma concentration time profile following the last measured concentration. It is calculated as (AUC \[0-∞\] minus AUC\[0-10\])\*100/ AUC (0-∞), where AUC (0-∞) = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUC(0-10) = area under the plasma concentration time-curve from zero (pre-dose) to the last quantifiable concentration.
| Percent AUC | Myrin 2 | Rimactane |
|---|---|---|
| Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated) | 18.84 ± 38.47 | 17.53 ± 30.23 |
Participants were evaluated for following safety laboratory tests: Hematology, chemistry, urinalysis.
| participants | Myrin 2 | Rimactane |
|---|---|---|
| Screening | 0 | 0 |
| Follow-up | 0 | 0 |
Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.
No measurements were reported for this outcome.
Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.
No measurements were reported for this outcome.
Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.
No measurements were reported for this outcome.
Mean change: vital sign value at observation (Day 1 and follow-up) minus vital sign value at baseline.
No measurements were reported for this outcome.
Any untoward medical occurrence in a participant who received study treatment was considered an AE without regard to possibility of causal relationship.
| participants | Myrin 2 | Rimactane |
|---|---|---|
| Day 0 | 0 | 0 |
| Day 1 | 0 | 0 |
| Follow-up | 0 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Myrin 2 | — | 0/20 (0%) | 0/20 (0%) |
| Rimactane | — | 0/21 (0%) | 0/21 (0%) |
| Age, Customized(participants) | Participants Eligible for Analysis |
|---|---|
| 18 to 22 years | 12 |
| 23 to 27 years | 4 |
| 28 to 32 years | 2 |
| 33 to 37 years | 2 |
| Sex: Female, Male(Participants) | Participants Eligible for Analysis |
|---|---|
| Female | 0 |
| Male | 20 |
The record gives a start of Apr 2011, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifampin